CBL-B inhibitor NX-1607

{
  "id": "MLC-T-ONC-012344",
  "term": "CBL-B inhibitor NX-1607",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, small-molecule inhibitor of Casitas B-lineage lymphoma proto-oncogene-b (CBL-B), with potential immunomodulatory and antineoplastic activities. Upon oral administration, CBL-B inhibitor NX-1607 targets, binds to and inhibits the activity of CBL-B, which may result in immune activation, the infiltration of natural killer (NK) cells and activated CD8+ T cells in the tumor microenvironment (TME), and the inhibition of tumor growth. CBL-B, an E3 ubiquitin ligase expressed in all leukocyte subsets including T cells and NK cells, is a negative regulator of immune activation.",
  "synonyms": [
    "Casitas B-lineage lymphoma proto-oncogene-b inhibitor NX-1607",
    "Casitas B-lineage lymphoma B inhibitor NX-1607"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cbl-b-inhibitor-nx-1607/"
}